CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

Pardanani, A., Lasho, T., Smith, G., Burns, C. J., Fantino, E. and Tefferi, A. (2009) CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 23 8: 1441-1445. doi:10.1038/leu.2009.50


Author Pardanani, A.
Lasho, T.
Smith, G.
Burns, C. J.
Fantino, E.
Tefferi, A.
Title CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
Formatted title
CYT387, a selective JAK1/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
Journal name Leukemia   Check publisher's open access policy
ISSN 0887-6924
1476-5551
Publication date 2009-08
Sub-type Article (original research)
DOI 10.1038/leu.2009.50
Volume 23
Issue 8
Start page 1441
End page 1445
Total pages 5
Place of publication London, Hamps, U.K.
Publisher Nature Publishing Group
Language eng
Formatted abstract
Somatic mutations in Janus kinase 2 (JAK2), including JAK2V617F, result in dysregulated JAK-signal transducer and activator transcription (STAT) signaling, which is implicated in myeloproliferative neoplasm (MPN) pathogenesis. CYT387 is an ATP-competitive small molecule that potently inhibits JAK1/JAK2 kinases (IC50=11 and 18nM, respectively), with significantly less activity against other kinases, including JAK3 (IC50=155nM). CYT387 inhibits growth of Ba/F3-JAK2V617F and human erythroleukemia (HEL) cells (IC50 ∼1500nM) or Ba/F3-MPLW515L cells (IC50=200nM), but has considerably less activity against BCR-ABL harboring K562 cells (IC=58000nM). Cell lines harboring mutated JAK2 alleles (CHRF-288-11 or Ba/F3-TEL-JAK2) were inhibited more potently than the corresponding pair harboring mutated JAK3 alleles (CMK or Ba/F3-TEL-JAK3), and STAT-5 phosphorylation was inhibited in HEL cells with an IC50=400nM. Furthermore, CYT387 selectively suppressed the in vitro growth of erythroid colonies harboring JAK2V617F from polycythemia vera (PV) patients, an effect that was attenuated by exogenous erythropoietin. Overall, our data indicate that the JAK1/JAK2 selective inhibitor CYT387 has potential for efficacious treatment of MPN harboring mutated JAK2 and MPL alleles.
Keyword Myeloproliferative neoplasm
Myelofibrosis
Janus kinase
Jak2v617f
Kinase inhibitor
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Faculty of Health and Behavioural Sciences -- Publications
ERA 2012 Admin Only
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 81 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 89 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 03 Oct 2011, 11:28:17 EST by System User on behalf of Child Health Research Centre